Advertisement

Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis

  • S. Sebastian
  • S. Myers
  • S. Nadir
  • S. Subramanian
Review
  • 30 Downloads

Abstract

Background

Pharmacokinetic data suggest that standard induction dosing schedules may not be sufficient in patients with acute severe colitis (ASUC). Hence, intensified induction regimes are increasingly used in the rescue treatment of hospitalized patients with ASUC to avoid the need for colectomy although the evidence for this is uncertain.

Aim

To conduct a systematic review of short- and long-term efficacy outcomes from accelerated infliximab induction studies.

Methods

Systematic search of relevant databases (MEDLINE, EMBASE, Cochrane Database of Systematic Reviews) and relevant conference proceedings (Digestive Diseases Week, European Colitis and Crohn’s Organisation Congress, United European Gastroenterology Week) was done.

Results

We identified ten relevant studies with a total of 705 patients, of whom 308 received an intensified infliximab regime. Pooled analysis showed no difference in short-term or long-term colectomy rates in those receiving accelerated induction regimes when compared to standard induction. No significant differences in complication rates were identified.

Conclusions

The available uncontrolled studies so far do not suggest short-term or long-term benefit in using accelerated induction in hospitalized ASUC. The overall poor quality of available studies with confounding variables indicates the need for a randomized controlled trial with personalized risk stratification.

Keywords

Acute severe UC Rescue therapy Infliximab Accelerated induction 

Abbreviations

UC

Ulcerative colitis

ASUC

Acute severe ulcerative colitis

AI

Accelerated induction

SI

Standard induction

TNF α

Tumor necrosis factor alpha

Notes

Author’s contribution

SS, SM, and SN designed study concept and did searches and analysis. SS, SM, and SN drafted the manuscript.

Compliance with ethical standards

Conflict of interest

Shaji Sebastian holds research grants from Takeda, AbbVie, Warner Chilcott, Ferring, MSD, serves on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Cellgene, and Tillots Pharma, and has received speaker fees from Abbvie, Jaansen, Merck, Warner Chilcott, and Falk Pharma. Sree Subramanian has received speaker fee from MSD, Actavis, Abbvie, Takeda, Dr Falk pharmaceuticals, and Shire and received educational grant from MSD, Abbvie, and Actavis and is an advisory board member for Abbvie, Dr Falk pharmaceutics, and Vifor pharmaceuticals. Sally Myers and Syed Nadir have no conflicts to declare.

Ethical approval

As this is a systematic review no patient consent or ethical committee approval was sought.

References

  1. 1.
    Domenech E, Manosa M, Cabre E. An overview of the natural history of inflammatory bowel diseases. Dig Dis. 2014;32:320–327.CrossRefPubMedGoogle Scholar
  2. 2.
    Ananthakrishnan AN, McGinley EL, Binion DG, et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–276.CrossRefPubMedGoogle Scholar
  3. 3.
    Hardy TL, Bulmer E. Ulcerative colitis: a survey of ninety-five cases. Br Med Journal. 1933;2:812–815.CrossRefGoogle Scholar
  4. 4.
    Brown SR, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;10:8–29.CrossRefPubMedGoogle Scholar
  5. 5.
    Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.CrossRefPubMedGoogle Scholar
  6. 6.
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.CrossRefPubMedGoogle Scholar
  7. 7.
    Van Assche G, D’Haens G, Normal M, et al. Randomised, double blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–1031.CrossRefPubMedGoogle Scholar
  8. 8.
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid -refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83–88.CrossRefPubMedGoogle Scholar
  9. 9.
    Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998–1002.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology. 2005;128:1805–1811.CrossRefPubMedGoogle Scholar
  11. 11.
    Chaparro M, Burgueno P, Iglesias E, et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid ulcerative colitis: a multicentric study. Aliment Pharmacol Ther. 2012;35:275–283.CrossRefPubMedGoogle Scholar
  12. 12.
    Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as a rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411–419.CrossRefPubMedGoogle Scholar
  13. 13.
    Sjoberg M, Magnuson A, Bjork J, et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long term follow up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377–387.CrossRefPubMedGoogle Scholar
  14. 14.
    Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet.. 2012;380:1909–1915.CrossRefPubMedGoogle Scholar
  15. 15.
    Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporine or infliximab. Gut. 2018;67:237–243.CrossRefPubMedGoogle Scholar
  16. 16.
    Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed method, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tottrup A, Erichsen R, Svaerke C, et al. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open. 2012;2:e000823.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ungar B, Mazoor R, Weisshof R, et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:1293–1299.CrossRefPubMedGoogle Scholar
  19. 19.
    Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249–255.CrossRefPubMedGoogle Scholar
  20. 20.
    Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into faeces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–355 e2.CrossRefPubMedGoogle Scholar
  21. 21.
    Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211–1228.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe colitis. Aliment Pharmacol Ther. 2015;41:1094–1103.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Herfarth HH, Rogler G, Higgins PDR. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:336–338.CrossRefPubMedGoogle Scholar
  24. 24.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed April 2018.
  25. 25.
    McPheeters ML, Kripalini S, Peterson NB, Idowu RT, et al. Quality improvement interventions to address health disparities. Evidence report/technology assessment. Rockville (MD): Agency for Healthcare Research and Quality (US). 2012. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0049222/pdf/TOC.pdf. Accessed April 2018.
  26. 26.
    Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–335e1.Google Scholar
  27. 27.
    Sly N, Werner S, Pitt R, et al. Accelerated dosing of infliximab is not associated with improved colectomy rates in hospitalized severe ulcerative colitis patients. Am J Gastroenterol. 2017;8:S189.Google Scholar
  28. 28.
    Shah SC, Naymagon S, Panchal HJ, et al. Accelerated infliximab dosing increases 30-day colectomy in hospitalized ulcerative colitis patients: a propensity score analysis. Inflamm Bowel Dis. 2018;24:651–659.CrossRefPubMedGoogle Scholar
  29. 29.
    Choy MC, Seah D, Gorelik A, et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018;33:1347–1352.CrossRefPubMedGoogle Scholar
  30. 30.
    Govani SM, Waljee AK, Stidham RW, et al. Accelerated dosing of infliximab prevents colectomy within 90 days in only half of patients with severe ulcerative colitis. Gastroenterology. 2016;150:S106.CrossRefGoogle Scholar
  31. 31.
    Singh KS, Hart L, Al Khoury A, et al. Standard versus intensified infliximab rescue therapy for hospitalised paediatric patients with acute severe exacerbations of colitis-predominant inflammatory bowel disease. J Crohn`s Colitis. 2018; P667.Google Scholar
  32. 32.
    Al Khoury A, Chao C, Aruljothy A, et al. Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival. J Crohn`s Colitis. 2017;P495.Google Scholar
  33. 33.
    Gibson DJ, Doherty J, McNally M, et al. Medium to long-term outcomes in patients receiving accelerated dose infliximab induction for acute severe ulcerative colitis (ASUC) in a multicentre cohort. Gastroenterology. 2018;S 318.Google Scholar
  34. 34.
    An YK, Chen CY, White LS, et al. Accelerated doses of infliximab induction and endoscopic mucosal healing inpatients with acute severe ulcerative colitis. J Gastroenterol Hepatol. 2017;32:121.  https://doi.org/10.1111/jgh.13895.CrossRefGoogle Scholar
  35. 35.
    Nalagatla N, Falloon K, Gloria T, et al. Effect of accelerated infliximab induction on short and long-term outcomes of acute severe ulcerative colitis: a retrospective multicentre study and metaanalysis. Clinical Gastroenterol Hepatol. 2018 (in press).Google Scholar
  36. 36.
    Rofaiel R, Kohli S, Mura M, et al. A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab induced acute interstitial pneumonitis after an accelerated induction dosing schedule. BMJ Case Rep. 2017;12:2017.Google Scholar
  37. 37.
    Kevans D, Murthy SJ, Iacono A, et al. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142:S 384.Google Scholar
  38. 38.
    Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic features and presence of antidrug antibodies associated with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:251–258.CrossRefPubMedGoogle Scholar
  39. 39.
    Shah SC, Naymagon S, Cohen BL, et al. There is significant practice pattern variability in the management of the hospitalized ulcerative colitis patient at a tertiary care and IBD referral centre. J Clin Gastroenterol. 2018;52:333–338.Google Scholar
  40. 40.
    Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079–1087.CrossRefPubMedGoogle Scholar
  41. 41.
    Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–910.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Papa Michael K, Rivas-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohn`s Colitis. 2016;10:1015–1023.Google Scholar
  43. 43.
    Beswick L, Rosella O, Rosella G et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study. J Crohn`s Colitis. 2018;12:289–297.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.IBD UnitHull and East Yorkshire NHS TrustHullUK
  2. 2.Hull York Medical SchoolHullUK
  3. 3.The Royal Liverpool and Broad Green University Hospitals NHS Foundation TrustLiverpoolUK

Personalised recommendations